Bioventus Stock (NASDAQ:BVS)
Previous Close
$10.42
52W Range
$3.90 - $14.38
50D Avg
$10.54
200D Avg
$9.32
Market Cap
$680.48M
Avg Vol (3M)
$287.65K
Beta
0.84
Div Yield
-
BVS Company Profile
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
BVS Performance
Latest News
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business
Jan 03, 25 | 12:00 PM | zacks.comBioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
Jan 02, 25 | 8:00 AM | globenewswire.comIs Bioventus (BVS) Outperforming Other Medical Stocks This Year?
Dec 23, 24 | 10:40 AM | zacks.comWall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet
Dec 06, 24 | 10:55 AM | zacks.comBioventus Inc. (BVS) Q3 2024 Earnings Call Transcript
Nov 05, 24 | 12:26 PM | seekingalpha.comBioventus (BVS) Matches Q3 Earnings Estimates
Nov 05, 24 | 9:45 AM | zacks.comBioventus Reports Third Quarter Financial Results
Nov 05, 24 | 7:30 AM | globenewswire.comAre Medical Stocks Lagging Bioventus (BVS) This Year?
Nov 04, 24 | 10:45 AM | zacks.comShould Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?
Oct 29, 24 | 10:35 AM | zacks.comBioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
Oct 29, 24 | 7:30 AM | globenewswire.comBioventus Surges 73% in Three Months: Time to Buy the Stock?
Oct 22, 24 | 10:35 AM | zacks.comFirst September Gains in 5 Years? Buy 3 Breakout Stocks Now
Sep 23, 24 | 4:06 PM | zacks.comBioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
Sep 19, 24 | 1:50 PM | zacks.comBull Of The Day: Bioventus (BVS)
Aug 29, 24 | 8:10 AM | zacks.comExecutives Buying W. P. Carey And 2 Other Stocks
Aug 21, 24 | 7:37 AM | benzinga.com5 Small Drug Stocks to Buy as Innovation Reaches Peak
Aug 16, 24 | 9:20 AM | zacks.comHealing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
Aug 12, 24 | 11:01 AM | seekingalpha.comBioventus Inc. (BVS) Q2 2024 Earnings Call Transcript
Aug 11, 24 | 1:45 PM | seekingalpha.comBioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
Aug 07, 24 | 4:15 PM | globenewswire.comBioventus Reports Second Quarter Financial Results
Aug 06, 24 | 7:30 AM | globenewswire.comBIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Aug 02, 24 | 9:00 PM | globenewswire.comBioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
Jul 30, 24 | 7:30 AM | globenewswire.comHere's Why You Should Consider Buying Bioventus (BVS) Stock
Jun 05, 24 | 11:21 AM | zacks.com5 Small Drug Stocks to Buy From a Recovering Industry
May 24, 24 | 10:02 AM | zacks.com3 Stocks Under $10 With Mammoth Growth Prospects
May 23, 24 | 6:42 AM | investorplace.comLatest Sec Filing
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools